CN110772528A - Application of iris polysaccharide in preparation of medicine for preventing and treating leptospirosis - Google Patents
Application of iris polysaccharide in preparation of medicine for preventing and treating leptospirosis Download PDFInfo
- Publication number
- CN110772528A CN110772528A CN201911265637.2A CN201911265637A CN110772528A CN 110772528 A CN110772528 A CN 110772528A CN 201911265637 A CN201911265637 A CN 201911265637A CN 110772528 A CN110772528 A CN 110772528A
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- leptospirosis
- preventing
- iris
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides an application of tectori polysaccharide in preparing a medicament for preventing and treating leptospirosis, which adopts a standard substance of astragalus polysaccharide to inject the astragalus polysaccharide into golden yellow mice sensitive to leptospirosis in advance at a dose of 50mg/kg, can effectively control the infection of leptospirosis after infecting leptospirosis of 2X108/ml, and has a survival rate of 100 percent. The invention expands the medicinal range of the astragalus polysaccharide and provides a basis for developing new application of the iris polysaccharide.
Description
Technical Field
Leptospirosis (Leptospirosis) is a worldwide common zoonotic disease, called Leptospirosis for short, that is associated with occupational or living contacts and with exposure to leptospira, and is highly prevalent in flood-prone areas, and is particularly widespread in developing countries and tropical regions. The disease is susceptible to human and livestock, and the clinical manifestations after infection are various, so that diagnosis is not easy. The pathogen of the leptospirosis can continuously exist in the host, further spread to pollute the environment, infect other people and animals, and cause serious harm. Currently, the methods for preventing and treating leptospira are the injection of vaccines and the use of antibiotics.
Iris, namely Indian iris, fanglauca herbs, rhizoma anemarrhenae and the like, are originally produced in China and Japan, are perennial herbaceous plants with bitter, pungent and mild properties, and are common Chinese herbal medicines in China. Has the main functions of promoting blood circulation to remove blood stasis, dispelling wind and promoting diuresis, detoxifying and removing food retention. Can be used for treating traumatic injury, rheumatalgia, sore throat, food stagnation, abdominal distention, malaria, carbuncle, furuncle, toxic swelling, and traumatic hemorrhage. The research on the iris polysaccharide in China is less, and the iris lactuca polysaccharide is especially fresh in terms of preventing and treating leptospira.
Background
The invention discloses application of tectori polysaccharide in preparation of a medicament for preventing and treating leptospirosis, provides new medical application of tectori polysaccharide, and belongs to the technical field of medicines.
Disclosure of Invention
The invention aims to provide application of tectori polysaccharide as a medicament in preparing medicaments for preventing and treating leptospirosis, including the prevention of leptospirosis and the treatment after infection. The application of the tectoridin can reduce the abuse of antibiotics and can also effectively prevent and control leptospira outbreak.
The invention aims to provide application of tectori polysaccharide as a medicament in preparing medicaments for preventing and treating leptospirosis, including the prevention of leptospirosis and treatment after infection.
The polysaccharide of the iris of the invention is used as a medicament for preventing and treating leptospirosis.
The iris polysaccharide substance is used as a medicine for preventing and treating leptospira, and is suitable for any pharmaceutically acceptable carrier.
The pharmaceutical preparation is standard liquid preparation of tectorigenin, and the dosage of the pharmaceutical preparation is 5mg/ml by dissolving and diluting tectorigenin powder with normal saline, namely 10 mg/kg.
The tectorial polysaccharide can effectively control the infection of leptospira, reduce the inflammatory reaction of each organ and improve the survival rate of golden hamster to 100 percent.
The invention has the positive effects that:
provides a new medical application of the tectorigenin for preparing a medicine for preventing and treating leptospira; carrying out secondary development on the pharmacological action of the compound; the medicinal range of the iris polysaccharide is expanded; the invention can effectively reduce the use of antibiotics when treating and preventing leptospirosis, can also effectively prevent and control leptospirosis during outbreak, and has great effect on the healthy development of animal husbandry.
Description of the drawings:
FIG. 1 is a graph of the resistance of golden hamsters to leptospira infection following injection of tectori polysaccharide;
FIG. 2 is a graph of the scavenging effect of tectorigenin on leptospira within the body;
FIG. 3 shows the protective effect of tectorigenin on the major organs of golden hamster;
FIG. 4 shows that tectorigenin causes the expression level of important inflammatory factors in the body.
The specific implementation mode is as follows:
the present invention is further illustrated by the following examples, which do not limit the present invention in any way, and any modifications or changes that can be easily made by a person skilled in the art to the present invention will fall within the scope of the claims of the present invention without departing from the technical solution of the present invention.
Example 1
The polysaccharide extract of Iris tectorum can be used as medicine for preventing and treating leptospirosis.
Example 2
The tectori polysaccharide used as the medicine for preventing and treating leptospira is suitable for any pharmaceutically acceptable carrier.
Example 3
The pharmaceutical preparation is an iris polysaccharide standard liquid preparation, and the iris polysaccharide powder is dissolved and diluted by normal saline according to dosage.
Example 4
The pharmaceutical preparation is standard liquid preparation of tectorigenin, and the dosage of the pharmaceutical preparation is 5mg/ml by dissolving and diluting tectorigenin powder with normal saline, namely 10 mg/kg.
Test example 1
Application of tectorum polysaccharide in preventing leptospira infection
Experimental drugs:
the standard substance of iris polysaccharide was diluted with physiological saline at 5mg/ml and injected subcutaneously at a dose of 50mg/kg based on the body weight of golden hamster.
The experimental method comprises the following steps:
the experiment was divided into two groups, i.e., an experimental group and a control group, each of eight four-week-old golden hamster. The experimental group was injected with irises per dose according to body weight one week before infection, and the control group was injected with normal saline. One week later, 2 × 108 leptospira were intraperitoneally injected. And observing the survival rate.
The experimental results are as follows:
referring to fig. 1, the survival rate of the experimental group injected with iris polysaccharide was 50%, while all of the golden yellow mice of the control group died. Indicating that the tectorigenin can effectively prevent the infection of leptospira.
Test example 2
Iris polysaccharide has effect in clearing leptospira in organism
The experimental method comprises the following steps:
the golden hamster of the control group and the experimental group in experimental example 1 was sampled, the liver, kidney and lung of each group of golden hamster were collected, DNA extraction of leptospira in the tissue was performed, and then a fluorescent quantitative PCR experiment was performed to analyze the load of leptospira in each organ of golden hamster.
The experimental results are as follows:
referring to fig. 2, compared to the control group injected with physiological saline only, the mice injected with tectori polysaccharide had a significant decrease in the leptospira loading in liver, kidney and lung.
Test example 3
The control and experimental groups of golden hamster of test example 1 were sampled for liver, kidney and lung, RNA was extracted, and then, fluorescent quantitative PCR was performed to analyze the expression of Tlr2, Tlr4, IL-1 β and iNOS in the respective organs of golden hamster 2 days and 5 days after challenge.
The experimental results are as follows:
referring to FIG. 3, the expression of TLR2 mRNA in liver and kidney was significantly higher at 2dpi and lower at 5dpi in the test group injected with Iridan compared to the control group, however, the expression of TLR2 mRNA in lung was significantly reduced in the test group at the same time, the expression of TLR4 mRNA was reduced or induced to be reduced at 2dpi and significantly reduced at 5dpi in the test group, and the expression of IL-1 β was higher at 2dpi and lower at 5dpi in all organs compared to the control group injected with Iridan, these results indicate that Iridan caused the expression of a large amount of TLR2 and IL-1 β mRNA in organs at 2dpi and the reduction of expression of TLR2, TLR4 and IL-1 β at 5dpi, and that Iridan caused inflammatory storm to reach and prematurely reduce at 5dpi, thus exerting a golden mouse protective effect.
Test example 4
The golden hamster of the control group and the golden hamster of the experimental group in test example 1 was sampled for liver, kidney and lung to prepare pathological sections, and HE staining was performed. Observation was performed under an optical microscope at 200 times.
The experimental results are as follows:
referring to fig. 4, the liver, kidney and lung of the golden hamster of the control group all had bleeding and inflammatory lesions of different degrees, while the pathological changes of the liver, kidney and lung of the golden hamster of the experimental group were not particularly obvious and had substantially no bleeding points and inflammatory lesions.
Claims (3)
1. The medical application of iris polysaccharide in preparing medicines for preventing and treating leptospira disease is provided.
2. The tectori polysaccharide used as the medicine for preventing and treating leptospira is suitable for any pharmaceutically acceptable carrier.
3. The pharmaceutical preparation is a liquid preparation of astragalus polysaccharide standard substance, β -glucan powder is dissolved and diluted by normal saline according to the dosage, 5mg/ml, and the dosage of β -glucan is 10 mg/kg.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911265637.2A CN110772528B (en) | 2019-12-11 | 2019-12-11 | Application of iris polysaccharide as medicine in preparing medicine for preventing and treating leptospirosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911265637.2A CN110772528B (en) | 2019-12-11 | 2019-12-11 | Application of iris polysaccharide as medicine in preparing medicine for preventing and treating leptospirosis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110772528A true CN110772528A (en) | 2020-02-11 |
CN110772528B CN110772528B (en) | 2023-03-14 |
Family
ID=69394448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911265637.2A Active CN110772528B (en) | 2019-12-11 | 2019-12-11 | Application of iris polysaccharide as medicine in preparing medicine for preventing and treating leptospirosis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110772528B (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010053095A (en) * | 2008-08-29 | 2010-03-11 | Kowa Co | External preparation containing analgesic-antiinflammatory agent |
CN101912405A (en) * | 2010-08-11 | 2010-12-15 | 吉林大学 | Medicinal composition for treating cattle endometritis |
CN103417760A (en) * | 2013-08-13 | 2013-12-04 | 张玉明 | Traditional Chinese medicine tincture with toxicity expelling and anti-inflammation |
CN105641379A (en) * | 2014-11-13 | 2016-06-08 | 天津市中敖饲料有限公司 | Swine leptospirosis treating traditional Chinese medicine decocting liquid and preparation method thereof |
CN107496908A (en) * | 2017-09-04 | 2017-12-22 | 南京医科大学 | Application of the irisin in anti-inflammatory drug is prepared |
WO2019014389A1 (en) * | 2017-07-11 | 2019-01-17 | The Regents Of The University Of California | Stimuli-responsive polysaccharide antimicrobial agents |
-
2019
- 2019-12-11 CN CN201911265637.2A patent/CN110772528B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010053095A (en) * | 2008-08-29 | 2010-03-11 | Kowa Co | External preparation containing analgesic-antiinflammatory agent |
CN101912405A (en) * | 2010-08-11 | 2010-12-15 | 吉林大学 | Medicinal composition for treating cattle endometritis |
CN103417760A (en) * | 2013-08-13 | 2013-12-04 | 张玉明 | Traditional Chinese medicine tincture with toxicity expelling and anti-inflammation |
CN105641379A (en) * | 2014-11-13 | 2016-06-08 | 天津市中敖饲料有限公司 | Swine leptospirosis treating traditional Chinese medicine decocting liquid and preparation method thereof |
WO2019014389A1 (en) * | 2017-07-11 | 2019-01-17 | The Regents Of The University Of California | Stimuli-responsive polysaccharide antimicrobial agents |
CN107496908A (en) * | 2017-09-04 | 2017-12-22 | 南京医科大学 | Application of the irisin in anti-inflammatory drug is prepared |
Non-Patent Citations (8)
Title |
---|
GALLAGHER A: "Leptospirosis in a dog with uveitis and presumed cholecystitis" * |
LIU J: "Immune-enhanced effect of Iris polysaccharide is protective against leptospirosis" * |
傅文栋;: "中草药及其有效成分体外抗菌抗病毒研究进展" * |
刘鹏举等: "水溶性酸浆果多糖提取工艺的研究", 《黑龙江农业科学》 * |
夏碧丽;王砚春;郭晓奎;何平;华允芬;: "钩端螺旋体脂多糖的结构和功能分析" * |
朱文涛: "中草药在奶牛养殖中的应用", 《中兽医学杂志》 * |
杨恩慈等: "鸢尾黄素药理作用的研究进展", 《中南药学》 * |
王文静,等: "鸢尾属植物主要化学成分及其提取工艺研究进展" * |
Also Published As
Publication number | Publication date |
---|---|
CN110772528B (en) | 2023-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7125836B2 (en) | Method of cancer screening; method of cancer treatment; and method of diabetes treatment | |
CN102274314A (en) | Evergreen coccidian powder and preparation method thereof | |
CN103230506B (en) | Bone-setting medicament | |
CN110772528B (en) | Application of iris polysaccharide as medicine in preparing medicine for preventing and treating leptospirosis | |
CN102847021A (en) | Enema for treating ulcerative colitis and preparation method thereof | |
CN107137444A (en) | It is a kind of to treat Chinese medicine composition of swine fever and preparation method thereof | |
CN1273493C (en) | Angelica polysaccharide and its preparation and use | |
CN104998277B (en) | A kind of resisting toxoplasmosis prescription medicine and its screening technique | |
CN101347522A (en) | Nano 'Shuang Hualian' injection preparation for fowl and preparation thereof | |
CN103316103B (en) | Coccidian-expelling and dysentery-stopping mixture for livestock and preparation method thereof | |
CN104042621A (en) | Use of andrographolide and its derivatives in preparation of drugs for preventing and treating hand-foot-and-mouth disease | |
CN104274528B (en) | A kind of cassia bark polyphenol extract with immunosuppressive activity and its preparation method and application | |
CN1237983C (en) | Compound rhizome of Cyrtomium aspirin tablet | |
CN1985905A (en) | Chinese medicine preparation for preventing and treating intestinal adhesion after abdominal cavity operation and its preparing process and application | |
CN100339126C (en) | Chinese traditional medicine for preventing and treating biliary tract inflammation and its preparation process | |
CN1875976A (en) | Use of tanshinone compound in preparation of medicine for treating prostate hyperplasia | |
CN104435314A (en) | Medicament composition for treating osteoarthrosis and application of medicament composition | |
CN110840909A (en) | Medical application of astragalus polysaccharide in preparation of medicines for preventing and treating leptospirosis | |
CN114917285B (en) | Application of polysaccharide compound in medicine for preventing and treating respiratory tract virus infection | |
CN109568419A (en) | A kind of Morinda officinalis total iridoid glycoside and its preparation method and application | |
CN101966245B (en) | Compound injection for curing viral diseases in livestock and poultry and preparation method thereof | |
CN101112504A (en) | Chinese medicine for curing cancer and the method for preparing the oral liquid thereof | |
조다혜 et al. | Sparganosis of the Bilateral Breast: A Case Report | |
CN105395584A (en) | Application of Pien Tze Huang and preparation thereof to preparation of medicine for treating multiple sclerosis | |
CN106266500B (en) | A kind of Chinese medicine composition for treating the proliferation of mammary gland |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |